Literature DB >> 21814748

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Mark Mackiewicz1, Konrad Huppi, Jason J Pitt, Tiffany H Dorsey, Stefan Ambs, Natasha J Caplen.   

Abstract

The identification of molecular features that contribute to the progression of breast cancer can provide valuable insight into the pathogenesis of this disease. Deregulated microRNA expression represents one type of molecular event that has been associated with many different human cancers. In order to identify a miRNA/mRNA regulatory interaction that is biologically relevant to the triple-negative breast cancer genotype/phenotype, we initially conducted a miRNA profiling experiment to detect differentially expressed miRNAs in cell line models representing triple-negative (MDA-MB-231), ER(+) (MCF7), and HER-2 overexpressed (SK-BR-3) histotypes. We identified human miR-34a expression as being >3-fold down (from its median expression value across all cell lines) in MDA-MB-231 cells, and identified AXL as a putative mRNA target using multiple miRNA/target prediction algorithms. The miR-34a/AXL interaction was functionally characterized through ectopic overexpression experiments with a miR-34a mimic in two independent triple-negative breast cancer cell lines. In reporter assays, miR-34a binds to its putative target site within the AXL 3'UTR to inhibit luciferase expression. We also observed degradation of AXL mRNA and decreased AXL protein levels, as well as cell signaling effects on AKT phosphorylation and phenotypic effects on cell migration. Finally, we present an inverse correlative trend in miR-34a and AXL expression for both cell line and patient tumor samples.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814748      PMCID: PMC3381742          DOI: 10.1007/s10549-011-1690-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  57 in total

1.  Axl and Tyro3 modulate female reproduction by influencing gonadotropin-releasing hormone neuron survival and migration.

Authors:  Angela Pierce; Brian Bliesner; Mei Xu; Sheila Nielsen-Preiss; Greg Lemke; Stuart Tobet; Margaret E Wierman
Journal:  Mol Endocrinol       Date:  2008-09-11

2.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Authors:  Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

Review 3.  Triple-negative breast cancer--current status and future directions.

Authors:  O Gluz; C Liedtke; N Gottschalk; L Pusztai; U Nitz; N Harbeck
Journal:  Ann Oncol       Date:  2009-11-09       Impact factor: 32.976

Review 4.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

Review 5.  Triple-negative/basal-like breast cancer: review.

Authors:  Emad A Rakha; Ian O Ellis
Journal:  Pathology       Date:  2009-01       Impact factor: 5.306

6.  Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.

Authors:  Y Li; X Ye; C Tan; J-A Hongo; J Zha; J Liu; D Kallop; M J C Ludlam; L Pei
Journal:  Oncogene       Date:  2009-07-27       Impact factor: 9.867

Review 7.  MicroRNAs in Cancer.

Authors:  Ramiro Garzon; George A Calin; Carlo M Croce
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

8.  MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.

Authors:  Dongsheng Yan; Xiangtian Zhou; Xiaoyan Chen; Dan-Ning Hu; Xiang Da Dong; Jiao Wang; Fan Lu; LiLi Tu; Jia Qu
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-21       Impact factor: 4.799

9.  The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.

Authors:  Jan-Bart M Koorstra; Collins A Karikari; Georg Feldmann; Savita Bisht; Pamela Leal Rojas; G Johan A Offerhaus; Hector Alvarez; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2009-04-22       Impact factor: 4.742

10.  Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Authors:  Jessica Kao; Keyan Salari; Melanie Bocanegra; Yoon-La Choi; Luc Girard; Jeet Gandhi; Kevin A Kwei; Tina Hernandez-Boussard; Pei Wang; Adi F Gazdar; John D Minna; Jonathan R Pollack
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

View more
  47 in total

1.  Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.

Authors:  I-K Park; B Mundy-Bosse; S P Whitman; X Zhang; S L Warner; D J Bearss; W Blum; G Marcucci; M A Caligiuri
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

2.  Passenger strand loading in overexpression experiments using microRNA mimics.

Authors:  Rolf Søkilde; Inga Newie; Helena Persson; Åke Borg; Carlos Rovira
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 3.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

4.  Axl receptor tyrosine kinase expression in breast cancer.

Authors:  Timothy M D'Alfonso; Jeffrey Hannah; Zhengming Chen; Yifang Liu; Pengbo Zhou; Sandra J Shin
Journal:  J Clin Pathol       Date:  2014-06-05       Impact factor: 3.411

5.  Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.

Authors:  Kris G Hargraves; Lin He; Gary L Firestone
Journal:  Mol Carcinog       Date:  2015-03-19       Impact factor: 4.784

6.  Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.

Authors:  Robert Torka; Kinga Pénzes; Simone Gusenbauer; Christine Baumann; István Szabadkai; Lászlȯ Őrfi; György Kéri; Axel Ullrich
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

7.  MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1.

Authors:  Alexandra L McCubbrey; Joshua D Nelson; Valerie R Stolberg; Pennelope K Blakely; Lisa McCloskey; William J Janssen; Christine M Freeman; Jeffrey L Curtis
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

8.  The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

Authors:  J Boysen; S Sinha; T Price-Troska; S L Warner; D J Bearss; D Viswanatha; T D Shanafelt; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528

Review 9.  The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Authors:  Brian D Adams; Christine Parsons; Frank J Slack
Journal:  Expert Opin Ther Targets       Date:  2015-12-11       Impact factor: 6.902

10.  The bioinformatics analysis of miRNAs signatures differentially expressed in HER2(+) versus HER2(-) breast cancers.

Authors:  Weiwei Nie; Lei Jin; Yanru Wang; Zexing Wang; Xiaoxiang Guan
Journal:  Cancer Biother Radiopharm       Date:  2012-09-25       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.